In August, Pfizer (NYSE:PFE) announced its plan to acquire Global Blood Therapeutics (GBT) for $68.50 per share, or roughly $5.4 billion.
Today, the company announced that it had finalized the acquisition, giving it access to GBT’s portfolio of drug candidates for sickle cell disease (SCD).
The GBT acquisition also adds Oxbryta (voxelotor), a novel sickle hemoglobin inhibitor, to its portfolio. Oxbryta has won marketing approval in the U.S., the European Union, United Arab Emirates, Oman and Great Britain.
In 2021, Oxbryta generated $194.7 million in sales, representing a 57% year-over-year increase.
GBT won Orphan Drug and Rare Disease designations from FDA for GBT021601 (GBT601) and inclaclumab, respectively.
Pfizer has developed therapies for rare hematologic diseases for three decades.
The company has been on a spending spree of late.
In March, Pfizer wrapped up a $6.7 billion acquisition of Arena Pharmaceuticals. Two mont…